GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Shiller PE Ratio

Gilead Sciences (BUE:GILD) Shiller PE Ratio : 19.95 (As of Mar. 23, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences Shiller PE Ratio?

As of today (2025-03-23), Gilead Sciences's current share price is ARS34375.00. Gilead Sciences's E10 for the quarter that ended in Dec. 2024 was ARS1,722.64. Gilead Sciences's Shiller PE Ratio for today is 19.95.

The historical rank and industry rank for Gilead Sciences's Shiller PE Ratio or its related term are showing as below:

BUE:GILD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.93   Med: 13.75   Max: 58.16
Current: 18.1

During the past years, Gilead Sciences's highest Shiller PE Ratio was 58.16. The lowest was 9.93. And the median was 13.75.

BUE:GILD's Shiller PE Ratio is ranked better than
67.53% of 462 companies
in the Drug Manufacturers industry
Industry Median: 24.305 vs BUE:GILD: 18.10

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Gilead Sciences's adjusted earnings per share data for the three months ended in Dec. 2024 was ARS1,434.200. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is ARS1,722.64 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Gilead Sciences Shiller PE Ratio Historical Data

The historical data trend for Gilead Sciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Shiller PE Ratio Chart

Gilead Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.58 12.80 13.87 12.26 15.79

Gilead Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.26 11.78 11.26 13.98 15.79

Competitive Comparison of Gilead Sciences's Shiller PE Ratio

For the Drug Manufacturers - General subindustry, Gilead Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Shiller PE Ratio falls into.



Gilead Sciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Gilead Sciences's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=34375.00/1722.64
=19.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Gilead Sciences's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=1434.2/133.1571*133.1571
=1,434.200

Current CPI (Dec. 2024) = 133.1571.

Gilead Sciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 24.342 99.621 32.536
201506 26.533 100.684 35.091
201509 28.771 100.392 38.161
201512 41.159 99.792 54.920
201603 36.948 100.470 48.969
201606 36.068 101.688 47.230
201609 37.143 101.861 48.555
201612 37.095 101.863 48.491
201703 31.605 102.862 40.913
201706 38.417 103.349 49.497
201709 36.098 104.136 46.158
201712 -56.521 104.011 -72.359
201803 23.574 105.290 29.813
201806 34.667 106.317 43.419
201809 58.878 106.507 73.611
201812 0.087 105.998 0.109
201903 60.199 107.251 74.740
201906 65.678 108.070 80.925
201909 -51.452 108.329 -63.244
201912 126.720 108.420 155.632
202003 75.725 108.902 92.591
202006 -182.104 108.767 -222.939
202009 21.530 109.815 26.106
202012 100.097 109.897 121.283
202103 123.410 111.754 147.045
202106 114.623 114.631 133.147
202109 200.449 115.734 230.625
202112 30.297 117.630 34.296
202203 2.147 121.301 2.357
202206 109.500 125.017 116.630
202209 197.309 125.227 209.805
202212 217.945 125.222 231.756
202303 158.040 127.348 165.249
202306 199.200 128.729 206.053
202309 605.414 129.860 620.788
202312 411.540 129.419 423.425
202403 -2,813.950 131.776 -2,843.438
202406 1,155.195 132.554 1,160.453
202409 950.500 133.029 951.416
202412 1,434.200 133.157 1,434.200

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Gilead Sciences  (BUE:GILD) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Gilead Sciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Address
333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).